JNJ JOHNSON & JOHNSON

2026Q1 · CUSIP 478160104 · Big Pharma · Sector: Healthcare & Biotech

Lit · Institutions accelerating in

Holders

4,609

Δ holders QoQ

+89

Breadth percentile

Top 2%

Whale holders

368

Δ whales

-5

Inst. holding value

$416.4B

New positions

301

Closed positions

212

Price momentum (1Q)

-5.4%

Put / Call

55/49

Breadth history (34 quarters)

Past Lit Events & Aftermath 17 lit events

Period	Percentile	Next-1Q return	Next-2Q return
2026Q1	Top 2%	—	—
2025Q4	Top 0%	-5.4%	—
2025Q3	Top 1%	+24.5%	+16.2%
2025Q1	Top 4%	+17.6%	+33.0%
2024Q4	Top 1%	-1.6%	+15.7%
2024Q3	Top 1%	+6.6%	+0.2%
2023Q4	Top 1%	-1.2%	+2.8%
2023Q2	Top 16%	-13.7%	-7.0%
2022Q4	Top 1%	+0.9%	+10.6%
2022Q1	Top 4%	-5.7%	-2.3%
2021Q4	Top 0%	+5.6%	+1.0%
2021Q2	Top 16%	-6.7%	-5.7%
2021Q1	Top 5%	+5.0%	-2.0%
2020Q4	Top 0%	+3.9%	+9.1%
2020Q2	Top 3%	+1.3%	+12.7%
2019Q4	Top 0%	+1.6%	+1.2%
2018Q4	Top 0%	+2.7%	-1.2%

Show all 17 events

Options Sentiment

Put holders

QoQ: +5

Call holders

QoQ: -2

See methodology →

Fundamentals

PE (TTM)

28.8

EPS (TTM)

$8.63

EPS YoY

-4.0%

Revenue (TTM)

$96.4B

Revenue YoY

+7.9%

Net margin

21.8%

ROE

25.9%

Debt ratio

59.6%

FCF (TTM)

$17.8B

Dividend (TTM)

$5.20

Quarterly Revenue & EPS (4Y)

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time

P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden

As of 2026-03-29 · SEC filings (XBRL)

Get the next update

2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.